Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCAPE Trial: Personalized Immunotherapy for SARS-CoV-2-associated Organ Dysfunction
2020-001039-29Phase 2Completed
- Sponsor
- Hellenic Institute for the Study of Sepsis
- Start
- Mar 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of anakinra and tocilizumab in coronavirus disease 2019 (COVID-19), organ dysfunction and viral pneumonia (2 arms), sponsored by Hellenic Institute for the Study of Sepsis. Primary endpoint: Composite clinical improvement at day 8. Started Mar 2020; status: completed.
02
Drugs
anakinratocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)organ dysfunctionviral pneumonia
Beyond the preview
Go deeper on 2020-001039-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001039-29.